– Scheduled to Reconvene on July 2, 2019 –
– Company urgently encourages stockholders to vote –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced
that its 2019 Annual Meeting of Stockholders, scheduled for June 11,
2019, was convened and adjourned without any business being conducted
due to the fact that quorum was not achieved. The Annual Meeting will be
reconvened July 2, 2019 to allow more opportunity for stockholders to
vote on all proposals described in the Company’s definitive proxy
statement filed with the Securities and Exchange Commission (SEC) on
April 25, 2019.
It has come to the Company’s attention that certain stockholders may
have been unable to vote their shares through their broker or financial
institutions, particularly if such shares are held through European
institutions. The Company encourages any stockholder that has not
received communications from their brokers or banks or is uncertain if
its shares have been voted to contact the Company’s proxy specialists at
the number listed below in order to help facilitate the voting of shares.
In order for the Company to achieve quorum, the Company’s board of
directors and management respectfully requests all such holders as of
the record date to please vote their proxies as soon as possible, but no
later than July 1, 2019 at 11:59 pm ET. The Company also reminds holders
to inquire with their voting institutions about any additional clearing
time that may be required to forward voting instructions to the Company
in advance of the July 1, 2019 deadline. The record date for the Annual
Meeting remains April 22, 2019. Company stockholders as of the record
date can vote, even if they have subsequently sold their shares.
Stockholders who have previously submitted their proxy or otherwise
voted and who do not want to change their vote need not take any action.
For questions relating to the voting of shares or to request additional
or misplaced proxy voting materials, the Company’s proxy specialists may
be reached at 1-888-742-1305 between the hours of 9:00 a.m. and 6:00
p.m. Eastern time Monday through Friday.
Stockholders who hold their shares through a bank or broker can vote
through Broadridge using one of the methods below:
| Vote By Internet | Vote By Telephone | Vote By Mail | ||
|
Use the Internet to transmit your voting instructions until 11:59 |
1-800-454-8683(VOTE)
Use any touch-tone telephone to transmit your voting instructions |
Mark, sign and date your proxy card and return it in the enclosed |
Registered stockholders (stockholders who do not hold their
shares through a bank or broker) are urged to complete, sign, date and
mail their proxy card at their earliest convenience. Any registered
stockholder who would like to vote by telephone may call 866-894-0536.
Registered stockholders may also vote online at www.cstproxyvote.com.
A copy of the company’s proxy statement as previously filed with the SEC
is available at no charge on the SEC website at www.sec.gov.
In addition, copies of the proxy statement and other documents may be
obtained free of charge by accessing the Company’s website at www.invivotherapeutics.com
or by contacting the Company’s Corporate Secretary at 617-710-1233 or by
mail to Corporate Secretary, InVivo Therapeutics, One Kendall Square,
Building 1400 West, Floor 4, Cambridge, MA 02139.
YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY!
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. The publicly traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Contacts
IR CONTACT:
Bret Shapiro, Managing Partner
CORE IR
Phone:
(516) 222-2560
brets@coreir.com
MEDIA CONTACT:
Jules Abraham
CORE IR
Phone: (917)
885-7378
julesa@coreir.com